Investigational therapies targeting the ErbB (EGFR, HER2, HER3, HER4) family in GI cancers

Author： Desai Monica Dandona   Saroya Bikramajit Singh   Lockhart Albert Craig  

Publisher： Informa Healthcare

ISSN： 1354-3784

Source： Expert Opinion on Investigational Drugs, Vol.22, Iss.3, 2013-03, pp. : 341-356

Disclaimer: Any content in publications that violate the sovereignty, the constitution or regulations of the PRC is not accepted or approved by CNPIEC.

Previous Menu Next

Abstract

Related content

Insight into the Medicinal Chemistry of EGFR and HER-2 Inhibitors

By  

Current Medicinal Chemistry, Vol. 21, Iss. 11, 2014-04 ,pp. : 1336-1350

Bentham Science Publishers

Access to resources Recommend Favorite

Anti-erbB-2 antibody trastuzumab in the treatment of HER2-amplified breast cancer

By Yeon Christina   Pegram Mark  

Investigational New Drugs, Vol. 23, Iss. 5, 2005-10 ,pp. : 391-409

Springer Publishing Company

Access to resources Recommend Favorite

Targeting EGFR and HER2 with 211At-Labeled Molecules: Unexpected and Expected Dose-Effect Relations in Cultured Tumor Cells

By  

Current Radiopharmaceuticals, Vol. 1, Iss. 3, 2008-09 ,pp. : 225-233

Bentham Science Publishers

Access to resources Recommend Favorite

HER2 Targeted Therapies for Cancer and the Gastrointestinal Tract

By  

Current Drug Targets, Vol. 10, Iss. 6, 2009-06 ,pp. : 537-542

Bentham Science Publishers

Access to resources Recommend Favorite

Targeting HER Receptors in Cancer

By  

Current Pharmaceutical Design, Vol. 19, Iss. 5, 2013-02 ,pp. : 808-817

Bentham Science Publishers

Access to resources Recommend Favorite